Ocular Therapeutix (OCUL) Non Operating Income (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Non Operating Income of $3.3 million for Q2 2026, up 2034.1% year-over-year from $156787.1 in Q2 2025, and down 29.23% on a QoQ basis from $4.7 million in Q1 2026.
Ocular Therapeutix (OCUL) Non Operating Income (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Non Operating Income for 14 years, with the latest figure at $3.3 million in Q2 2026.
- Non Operating Income for Q2 2026 came in at $3.3 million, up 2034.1% year-over-year; the trailing twelve-month figure through Jun 2026 was $12.5 million (up 9.45% YoY), and the FY2025 annual result was $4.1 million, up 118.77% from the prior year.
- Non Operating Income slipped to $3.3 million in Q2 2026, from $4.7 million in the prior quarter.
- Over five years, Non Operating Income peaked at $18.7 million in Q3 2023 and troughed at -$33.2 million in Q1 2024.
- A 5-year average of -$17277.8 and a median of $519000.0 in 2022 frame the typical range for Non Operating Income.
- The widest annual swing landed in 2023, when Non Operating Income sank 340.12%; it then soared 3576.47% in 2026.
- A 5-year view of Non Operating Income shows it stood at $3.8 million in 2022, then sank by 340.12% to -$9.2 million in 2023, then surged by 123.86% to $2.2 million in 2024, then soared by 133.36% to $5.1 million in 2025, then slumped by 34.47% to $3.3 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $3.3 million in Q2 2026, $4.7 million in Q1 2026, and $5.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 3.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.35 Mn |
| Mar 31, 2026 | 4.73 Mn |
| Dec 31, 2025 | 5.11 Mn |
| Sep 30, 2025 | -720,000.00 |
| Jun 30, 2025 | -173,000.00 |
| Mar 31, 2025 | -136,000.00 |
| Dec 31, 2024 | 2.19 Mn |
| Sep 30, 2024 | 9.51 Mn |
| Jun 30, 2024 | -187,000.00 |
| Mar 31, 2024 | -33.23 Mn |
| Dec 31, 2023 | -9.17 Mn |
| Sep 30, 2023 | 18.70 Mn |
| Jun 30, 2023 | -112,000.00 |
| Mar 31, 2023 | -7.77 Mn |
| Dec 31, 2022 | 3.82 Mn |
| Sep 30, 2022 | -2.64 Mn |
| Jun 30, 2022 | 1.15 Mn |
| Mar 31, 2022 | 5.29 Mn |
| Dec 31, 2021 | 14.20 Mn |
| Sep 30, 2021 | 22.19 Mn |